Abstract:Highlights • Probiotics reduced the depression rating scores of MDD patients. • Probiotics ameliorate the gastrointestinal problems of MDD patients. • Probiotics caused slight perturbation on the patients' gut microbiome. • Probiotics improved the gut motility of stressed mice. • Probiotics' gut-brain beneficial effect correlates to their regulation of serotonin. Introduction Major depressive disorder (MDD) is a leading global psychiatric disease. MDD is highly comorbid with gastrointestinal abnormalities, such as gut motility dysfunction. An effective strategy to manage depression and its accompanying gastrointestinal symptoms is warranted. Objectives Three probiotic strains ( Bifidobacterium breve CCFM1025, Bifidobacterium longum CCFM687, and Pediococcus acidilactici CCFM6432) had previously been validated in mice to possess antidepressant-like potential. This study investigated the potential psychotropic effects of a combined three-strain probiotic intervention for human MDD patients. The mechanism of action was further investigated in the stress-induced depression mice model. Methods MDD patients were given a freeze-dried, mixed probiotic formula for four weeks. The patients' psychometric and gastrointestinal conditions were evaluated using clinical rating scales before and after treatment. Their gut microbiome was also analysed using 16S rRNA gene amplicon sequencing. The mechanisms underlying the beneficial probiotic effects were determined using a chronic stress-induced depressive mouse model. Results Multi-probiotics significantly reduced depression scores, and to a greater extent than the placebo (based on the Hamilton Depression Rating, Montgomery-Asberg Depression Rating, and Brief Psychiatric Rating Scales). Multi-probiotics also significantly improved the patients' gastrointestinal functions (based on self-evaluation using the Gastrointestinal Symptom Rating Scale). Serotonergic system modification was demonstrated as the key mechanism behind the probiotics' benefits for the brain and the gut. Conclusion Our findings suggest a novel and promising treatment to manage MDD and accompanying gut motility problems, and provide options for treating other gut-brain axis-related disorders. Graphical abstract Download : Download high-res image (82KB) Download : Download full-size image

Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder

Gut Microbial Clues to Bipolar Disorder: State‐of‐the‐art Review of Current Findings and Future Directions

A pilot exploration of multi-omics research of gut microbiome in major depressive disorders

Characteristics of gut microbiota and metabolic phenotype in patients with major depressive disorder based on multi-omics analysis

Multi-omics data reveals the important role of glycerophospholipid metabolism in the crosstalk between gut and brain in depression

Multiomics Study of Gut Bacteria and Host Metabolism in Irritable Bowel Syndrome and Depression Patients

Integrated multi-omics analysis reveals gut microbiota dysbiosis and systemic disturbance in major depressive disorder

Core Antibiotic Resistance Genes Mediate Gut Microbiota to Intervene in the Treatment of Major Depressive Disorder

The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option

Multi-Probiotics ameliorate Major depressive disorder and accompanying gastrointestinal syndromes via serotonergic system regulation

Depression-associated gut microbes, metabolites and clinical trials

Microbiota-gut-brain axis: Natural antidepressants molecular mechanism

Altered gut bacterial-fungal interkingdom networks in children and adolescents with depression

Gut microbiota and its metabolites in depression: from pathogenesis to treatment

Relationships between the gut microbiome and brain functional alterations in first-episode, drug-naïve patients with major depressive disorder

Baseline gut microbiota profiles affect treatment response in patients with depression

Proteomics analysis of the gut–brain axis in a gut microbiota-dysbiosis model of depression

Research Progress on Mechanisms of Modulating Gut Microbiota to Improve Symptoms of Major Depressive Disorder

Association analysis of gut microbiota and efficacy of SSRIs antidepressants in patients with major depressive disorder

Current landscape of fecal microbiota transplantation in treating depression

Gut microbiota modulates neurotransmitter and gut-brain signaling